Middle East Pharmaceutical Industries Company
Saudi ExchangeTotal Valuation
Middle East Pharmaceutical Industries Company carries a market capitalization of 2.13B, placing it among publicly traded companies globally. Its enterprise value stands at 2.01B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.13B |
| Enterprise Value | 2.01B |
Share Statistics
Middle East Pharmaceutical Industries Company currently has 35.00M shares outstanding.
| Shares Outstanding | 35.00M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Middle East Pharmaceutical Industries Company trades at a trailing price-to-earnings ratio of 18.65. The price-to-sales ratio is 3.95, and the price-to-book ratio stands at 4.53.
| PE Ratio | 18.65 |
| PS Ratio | 3.95 |
| PB Ratio | 4.53 |
| P/TBV Ratio | 5.51 |
| P/FCF Ratio | 16.28 |
| P/OCF Ratio | 25.43 |
Enterprise Valuation
On an enterprise value basis, Middle East Pharmaceutical Industries Company trades at an EV/EBITDA multiple of 17.07 and an EV/FCF ratio of 16.20. The EV/Sales ratio of 4.08 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 17.07 provides insight into valuation relative to core operating earnings.
| EV / Sales | 4.08 |
| EV / EBITDA | 17.07 |
| EV / EBIT | 17.07 |
| EV / FCF | 16.20 |
Financial Position
Middle East Pharmaceutical Industries Company maintains a current ratio of 2.85, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.99, indicating elevated leverage, while an interest coverage ratio of 24.09 demonstrates strong ability to service its debt obligations.
| Current Ratio | 2.85 |
| Quick Ratio | 0.13 |
| Debt / Equity | 19.99 |
| Debt / EBITDA | 0.71 |
| Interest Coverage | 24.09 |
Financial Efficiency
Middle East Pharmaceutical Industries Company posts a return on equity of 25.98 and a return on invested capital of 23.29.
| Return on Equity (ROE) | 25.98 |
| Return on Assets (ROA) | 17.79 |
| Return on Invested Capital (ROIC) | 23.29 |
| Return on Capital Employed (ROCE) | 22.95 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.90 |
Taxes
Over the trailing twelve months, Middle East Pharmaceutical Industries Company has paid 7.42M in income taxes, reflecting an effective tax rate of 6.63.
| Income Tax | 7.42M |
| Effective Tax Rate | 6.63 |
Stock Price Statistics
Middle East Pharmaceutical Industries Company's stock has declined approximately -12.06248% over the past 52 weeks. The 50-day moving average sits at 59.73, while the 200-day moving average is 64.14.
| Beta (5Y) | N/A |
| 52-Week Price Change | -12.06248% |
| 50-Day Moving Average | 59.73 |
| 200-Day Moving Average | 64.14 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Middle East Pharmaceutical Industries Company generated 493.25M in revenue and converted that into 104.51M in net income, yielding earnings per share of 2.99. EBITDA reached 117.97M, while operating income came in at 117.97M.
| Revenue | 493.25M |
| Gross Profit | 307.19M |
| Operating Income | 117.97M |
| Pretax Income | 111.93M |
| Net Income | 104.51M |
| EBITDA | 117.97M |
| EBIT | 117.97M |
| Earnings Per Share (EPS) | 2.99 |
Balance Sheet
Middle East Pharmaceutical Industries Company holds 18.82M in cash and equivalents against 83.44M in total debt, resulting in a net debt position of 64.15M. Total book value stands at 430.47M, with working capital of 278.57M providing operational flexibility.
| Cash & Cash Equivalents | 18.82M |
| Total Debt | 83.44M |
| Net Debt | 64.15M |
| Equity (Book Value) | 430.47M |
| Book Value Per Share | 12.30 |
| Working Capital | 278.57M |
Cash Flow
Middle East Pharmaceutical Industries Company produced 76.64M in operating cash flow over the past twelve months. After subtracting -43.09M in capital expenditures, free cash flow totaled 33.55M - equivalent to 0.96 per share.
| Operating Cash Flow | 76.64M |
| Capital Expenditures | -43.09M |
| Free Cash Flow | 33.55M |
| FCF Per Share | 0.96 |
Margins
Middle East Pharmaceutical Industries Company operates with a gross margin of 62.28, reflecting its pricing power and cost economics. The operating margin of 23.92 and net profit margin of 21.19 provide insight into operational efficiency.
| Gross Margin | 62.28 |
| Operating Margin | 23.92 |
| Pretax Margin | 22.69 |
| Profit Margin | 21.19 |
| EBITDA Margin | 23.92 |
Dividends & Yields
The company's payout ratio of 46.31 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 1.38 |
| Dividend Yield | N/A |
| Payout Ratio | 46.31 |
| Shareholder Yield | 2.77 |
| FCF Yield | 6.14 |
Stock Splits
Middle East Pharmaceutical Industries Company's most recent stock split took place on May 12, 2026 with a 4:7 split ratio.
| Last Split Date | 5/12/2026 |
| Split Ratio | 4:7 |
Scores
Middle East Pharmaceutical Industries Company posts an Altman Z-Score of 8.33, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 8.33 |